At a glance
ClinicalIndex Comparison Record- ✓Age ≥50 years
- ✓Post-albuterol FEV1/FVC ratio ≤0.70 (COPD diagnostic criterion)
- ✓Post-albuterol FEV1 <80% of predicted normal
- ✓Smoking history ≥10 pack-years (current or former smoker)
- ✕Current diagnosis of asthma
- ✕BMI ≥35 kg/m²
- ✕Respiratory diagnosis other than COPD (e.g., lung cancer, bronchiectasis, sarcoidosis, tuberculosis, lung fibrosis)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 4 clinical trial evaluating ADVAIR DISKUS™ 250/50mcg and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 249 participants across 24 sites.
Detailed Summary
The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.
Study Details
Timeline
Interventions
ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
COPD subjects-Placebo DISKUS